Dupilumab improves patient-reported outcomes in patients with chronic rhinosinusitis with nasal polyps and comorbid asthma

Claus Bachert; Peter W. Hellings; Joaquim Mullol; Robert M. Naclerio; Jingdong Chao; Nikhil Amin; Annette Grabher; Brian N. Swanson; Jennifer D. Hamilton; Sophie Guillonneau; Christine Taniou; Donghui Zhang; Gianluca Pirozzi; Neil M.H. Graham; Heribert Staudinger; Leda P. Mannent; Asif Khan

doi:10.1016/j.jaip.2019.03.023

Dupilumab improves patient-reported outcomes in patients with chronic rhinosinusitis with nasal polyps and comorbid asthma

Claus Bachert, Peter W. Hellings, Joaquim Mullol, Robert M. Naclerio, Jingdong Chao, Nikhil Amin, Annette Grabher, Brian N. Swanson, Jennifer D. Hamilton, Sophie Guillonneau, Christine Taniou, Donghui Zhang, Gianluca Pirozzi, Neil M.H. Graham, Heribert Staudinger, Leda P. Mannent, Asif Khan

Research output: Contribution to journal › Article › peer-review

31 Scopus citations

Original language	English
Pages (from-to)	2447-2449.e2
Journal	Journal of Allergy and Clinical Immunology: In Practice
Volume	7
Issue number	7
DOIs	https://doi.org/10.1016/j.jaip.2019.03.023
State	Published - Sep 1 2019
Externally published	Yes

Access to Document

10.1016/j.jaip.2019.03.023

Cite this

Bachert, C., Hellings, P. W., Mullol, J., Naclerio, R. M., Chao, J., Amin, N., Grabher, A., Swanson, B. N., Hamilton, J. D., Guillonneau, S., Taniou, C., Zhang, D., Pirozzi, G., Graham, N. M. H., Staudinger, H., Mannent, L. P., & Khan, A. (2019). Dupilumab improves patient-reported outcomes in patients with chronic rhinosinusitis with nasal polyps and comorbid asthma. Journal of Allergy and Clinical Immunology: In Practice, 7(7), 2447-2449.e2. https://doi.org/10.1016/j.jaip.2019.03.023

Bachert, Claus ; Hellings, Peter W. ; Mullol, Joaquim ; Naclerio, Robert M. ; Chao, Jingdong ; Amin, Nikhil ; Grabher, Annette ; Swanson, Brian N. ; Hamilton, Jennifer D. ; Guillonneau, Sophie ; Taniou, Christine ; Zhang, Donghui ; Pirozzi, Gianluca ; Graham, Neil M.H. ; Staudinger, Heribert ; Mannent, Leda P. ; Khan, Asif. / Dupilumab improves patient-reported outcomes in patients with chronic rhinosinusitis with nasal polyps and comorbid asthma. In: Journal of Allergy and Clinical Immunology: In Practice. 2019 ; Vol. 7, No. 7. pp. 2447-2449.e2.

@article{e12930e00eb54d04bebe2586aac0048c,

title = "Dupilumab improves patient-reported outcomes in patients with chronic rhinosinusitis with nasal polyps and comorbid asthma",

author = "Claus Bachert and Hellings, {Peter W.} and Joaquim Mullol and Naclerio, {Robert M.} and Jingdong Chao and Nikhil Amin and Annette Grabher and Swanson, {Brian N.} and Hamilton, {Jennifer D.} and Sophie Guillonneau and Christine Taniou and Donghui Zhang and Gianluca Pirozzi and Graham, {Neil M.H.} and Heribert Staudinger and Mannent, {Leda P.} and Asif Khan",

note = "Funding Information: Editorial assistance was provided by Bilge Yoruk, PhD, and Ravi Subramanian, PhD, of Excerpta Medica funded by Sanofi Genzyme and Regeneron Pharmaceuticals . Funding Information: The research was sponsored by Sanofi and Regeneron Pharmaceuticals.Conflicts of interest: C. Bachert is the principal investigator of the study, and serves on the advisory boards of ActoBiotics, ALK, ASIT Biotech, AstraZeneca, Novartis, Sanofi, and Stallergenes. P. W. Hellings serves on the advisory board of Regeneron Pharmaceuticals, Inc. J. Mullol is the member of national and international scientific advisory boards (consulting) of and receives fees for lectures and grants for research projects from ALK-Abell?, Allakos, FAES, Genentech, Glenmark, GSK, Mylan, Menarini, MSD, Novartis, Regeneron Pharmaceuticals, Sanofi Genzyme, UCB, and Uriach. R. M. Naclerio serves on the advisory board of ActoBiotics, Genentech, Novartis, and Sanofi; and is on the speaker's bureau of Optinose. J. Chao, N. Amin, J. D. Hamilton, and N. M. H. Graham are employees and shareholders of Regeneron Pharmaceuticals, Inc. A. Grabher, S. Guillonneau, D. Zhang, G. Pirozzi, H. Staudinger, L. P. Mannent, and A. Khan are employees of Sanofi and may hold stock and/or stock options in the company. B. N. Swanson is the former Sanofi employee and may hold stock or stock options in the company. C. Taniou is the employee of Altran Technologies.Editorial assistance was provided by Bilge Yoruk, PhD, and Ravi Subramanian, PhD, of Excerpta Medica funded by Sanofi Genzyme and Regeneron Pharmaceuticals. Funding Information: The research was sponsored by Sanofi and Regeneron Pharmaceuticals.Conflicts of interest: C. Bachert is the principal investigator of the study, and serves on the advisory boards of ActoBiotics, ALK, ASIT Biotech, AstraZeneca, Novartis, Sanofi, and Stallergenes. P. W. Hellings serves on the advisory board of Regeneron Pharmaceuticals, Inc. J. Mullol is the member of national and international scientific advisory boards (consulting) of and receives fees for lectures and grants for research projects from ALK-Abell{\'o}, Allakos, FAES, Genentech, Glenmark, GSK, Mylan, Menarini, MSD, Novartis, Regeneron Pharmaceuticals, Sanofi Genzyme, UCB, and Uriach. R. M. Naclerio serves on the advisory board of ActoBiotics, Genentech, Novartis, and Sanofi; and is on the speaker's bureau of Optinose. J. Chao, N. Amin, J. D. Hamilton, and N. M. H. Graham are employees and shareholders of Regeneron Pharmaceuticals, Inc. A. Grabher, S. Guillonneau, D. Zhang, G. Pirozzi, H. Staudinger, L. P. Mannent, and A. Khan are employees of Sanofi and may hold stock and/or stock options in the company. B. N. Swanson is the former Sanofi employee and may hold stock or stock options in the company. C. Taniou is the employee of Altran Technologies.Editorial assistance was provided by Bilge Yoruk, PhD, and Ravi Subramanian, PhD, of Excerpta Medica funded by Sanofi Genzyme and Regeneron Pharmaceuticals. Funding Information: The research was sponsored by Sanofi and Regeneron Pharmaceuticals . ",

year = "2019",

month = sep,

day = "1",

doi = "10.1016/j.jaip.2019.03.023",

language = "English",

volume = "7",

pages = "2447--2449.e2",

journal = "Journal of Allergy and Clinical Immunology: In Practice",

issn = "2213-2198",

number = "7",

}

Bachert, C, Hellings, PW, Mullol, J, Naclerio, RM, Chao, J, Amin, N, Grabher, A, Swanson, BN, Hamilton, JD, Guillonneau, S, Taniou, C, Zhang, D, Pirozzi, G, Graham, NMH, Staudinger, H, Mannent, LP & Khan, A 2019, 'Dupilumab improves patient-reported outcomes in patients with chronic rhinosinusitis with nasal polyps and comorbid asthma', Journal of Allergy and Clinical Immunology: In Practice, vol. 7, no. 7, pp. 2447-2449.e2. https://doi.org/10.1016/j.jaip.2019.03.023

Dupilumab improves patient-reported outcomes in patients with chronic rhinosinusitis with nasal polyps and comorbid asthma. / Bachert, Claus; Hellings, Peter W.; Mullol, Joaquim; Naclerio, Robert M.; Chao, Jingdong; Amin, Nikhil; Grabher, Annette; Swanson, Brian N.; Hamilton, Jennifer D.; Guillonneau, Sophie; Taniou, Christine; Zhang, Donghui; Pirozzi, Gianluca; Graham, Neil M.H.; Staudinger, Heribert; Mannent, Leda P.; Khan, Asif.

In: Journal of Allergy and Clinical Immunology: In Practice, Vol. 7, No. 7, 01.09.2019, p. 2447-2449.e2.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Dupilumab improves patient-reported outcomes in patients with chronic rhinosinusitis with nasal polyps and comorbid asthma

AU - Bachert, Claus

AU - Hellings, Peter W.

AU - Mullol, Joaquim

AU - Naclerio, Robert M.

AU - Chao, Jingdong

AU - Amin, Nikhil

AU - Grabher, Annette

AU - Swanson, Brian N.

AU - Hamilton, Jennifer D.

AU - Guillonneau, Sophie

AU - Taniou, Christine

AU - Zhang, Donghui

AU - Pirozzi, Gianluca

AU - Graham, Neil M.H.

AU - Staudinger, Heribert

AU - Mannent, Leda P.

AU - Khan, Asif

N1 - Funding Information: Editorial assistance was provided by Bilge Yoruk, PhD, and Ravi Subramanian, PhD, of Excerpta Medica funded by Sanofi Genzyme and Regeneron Pharmaceuticals . Funding Information: The research was sponsored by Sanofi and Regeneron Pharmaceuticals.Conflicts of interest: C. Bachert is the principal investigator of the study, and serves on the advisory boards of ActoBiotics, ALK, ASIT Biotech, AstraZeneca, Novartis, Sanofi, and Stallergenes. P. W. Hellings serves on the advisory board of Regeneron Pharmaceuticals, Inc. J. Mullol is the member of national and international scientific advisory boards (consulting) of and receives fees for lectures and grants for research projects from ALK-Abell?, Allakos, FAES, Genentech, Glenmark, GSK, Mylan, Menarini, MSD, Novartis, Regeneron Pharmaceuticals, Sanofi Genzyme, UCB, and Uriach. R. M. Naclerio serves on the advisory board of ActoBiotics, Genentech, Novartis, and Sanofi; and is on the speaker's bureau of Optinose. J. Chao, N. Amin, J. D. Hamilton, and N. M. H. Graham are employees and shareholders of Regeneron Pharmaceuticals, Inc. A. Grabher, S. Guillonneau, D. Zhang, G. Pirozzi, H. Staudinger, L. P. Mannent, and A. Khan are employees of Sanofi and may hold stock and/or stock options in the company. B. N. Swanson is the former Sanofi employee and may hold stock or stock options in the company. C. Taniou is the employee of Altran Technologies.Editorial assistance was provided by Bilge Yoruk, PhD, and Ravi Subramanian, PhD, of Excerpta Medica funded by Sanofi Genzyme and Regeneron Pharmaceuticals. Funding Information: The research was sponsored by Sanofi and Regeneron Pharmaceuticals.Conflicts of interest: C. Bachert is the principal investigator of the study, and serves on the advisory boards of ActoBiotics, ALK, ASIT Biotech, AstraZeneca, Novartis, Sanofi, and Stallergenes. P. W. Hellings serves on the advisory board of Regeneron Pharmaceuticals, Inc. J. Mullol is the member of national and international scientific advisory boards (consulting) of and receives fees for lectures and grants for research projects from ALK-Abelló, Allakos, FAES, Genentech, Glenmark, GSK, Mylan, Menarini, MSD, Novartis, Regeneron Pharmaceuticals, Sanofi Genzyme, UCB, and Uriach. R. M. Naclerio serves on the advisory board of ActoBiotics, Genentech, Novartis, and Sanofi; and is on the speaker's bureau of Optinose. J. Chao, N. Amin, J. D. Hamilton, and N. M. H. Graham are employees and shareholders of Regeneron Pharmaceuticals, Inc. A. Grabher, S. Guillonneau, D. Zhang, G. Pirozzi, H. Staudinger, L. P. Mannent, and A. Khan are employees of Sanofi and may hold stock and/or stock options in the company. B. N. Swanson is the former Sanofi employee and may hold stock or stock options in the company. C. Taniou is the employee of Altran Technologies.Editorial assistance was provided by Bilge Yoruk, PhD, and Ravi Subramanian, PhD, of Excerpta Medica funded by Sanofi Genzyme and Regeneron Pharmaceuticals. Funding Information: The research was sponsored by Sanofi and Regeneron Pharmaceuticals .

PY - 2019/9/1

Y1 - 2019/9/1

UR - http://www.scopus.com/inward/record.url?scp=85064194313&partnerID=8YFLogxK

U2 - 10.1016/j.jaip.2019.03.023

DO - 10.1016/j.jaip.2019.03.023

M3 - Article

C2 - 30928658

AN - SCOPUS:85064194313

VL - 7

SP - 2447-2449.e2

JO - Journal of Allergy and Clinical Immunology: In Practice

JF - Journal of Allergy and Clinical Immunology: In Practice

SN - 2213-2198

IS - 7

ER -

Dupilumab improves patient-reported outcomes in patients with chronic rhinosinusitis with nasal polyps and comorbid asthma

Access to Document

Other files and links

Fingerprint

Cite this